The compound KZ-001 involved in this study is a selective MEK inhibitor, superior to the listed MEK inhibitors; therefore, we investigated whether KZ-001 could enhance the radiosensitivity of KRASm lung cancer cell lines in vitro. Here, MAP2K7 is linked to lung cancer.